Adamas CFO Bill Dawson leaves abruptly

  • Push-out Score suggests push-out forces
  • After almost three years on the job
  • Accolades, praise and thanks for Dawson
  • Alf Merriweather taking over

(exechange) — Emeryville, California, June 28, 2017 — Bill Dawson, finance chief of Adamas, leaves. It is an abrupt change. As announced by Adamas Pharmaceuticals, Inc. in a news release and in a regulatory filing published on Wednesday, June 28, 2017, William J. (Bill) Dawson leaves the post as Chief Financial Officer at the pharmaceutical company in a surprising move after almost three years on the job, effective June 29, 2017.

Dawson’s duties are taken over by Alf Merriweather, most recently Chief Financial Officer at RainDance Technologies, Inc.

The fact that Dawson’s successor is brought in from outside suggests that the board may seek to stimulate change with fresh ideas and new initiatives.

No reason given

In the announcement, Adamas did not explicitly explain the obviously compelling reason for Dawson’s sudden move, opening the door for speculation.

Precise information about the future plans of Dawson was not immediately available.

“Retirement”

Adamas said: “On June 28, 2017, the Company announced the retirement of William Dawson, the Company’s Chief Financial Officer, effective June 29, 2017.”

“Not the result of any disagreement”

“Mr. Dawson’s separation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices,” Adamas said.

Great Point Partners holds 11.63 percent stake

Great Point Partners LLC reported an 11.63 percent stake in Adamas Pharmaceuticals, Inc. as of March 30, 2017.

Chaired by Gregory T. Went

Adamas Pharmaceuticals, Inc. is chaired by Gregory T. Went.

On the job as CFO since 2014

Dawson has served as the Company’s Chief Financial Officer since August 2014.

Prior to joining the Company, he was an independent consultant from April 2012 to August 2014.

Dawson previously served as Chief Financial Officer of Catalyst Biosciences, Inc., a privately‑held biotechnology company from March 2010 to April 2012, where he was responsible for the company’s finance, treasury, and IT functions.

From August 2004 to April 2009, Dawson served as Vice President, Finance and Chief Financial Officer of Cerus Corporation, a publicly‑held biomedical products company.

Prior to joining Cerus, Dawson served in a variety of senior financial positions at companies in the biotechnology, healthcare services and information technology, and investment banking industries.

Dawson has served as a member of the board of directors of McGrath RentCorp, a publicly held business‑to‑business rental company, since 1998 and as a member of the board of directors of Wellington Trust Company, a subsidiary of Wellington Management Company, LLP, a private institutional investment management company, since 2001.

Dawson received a Bachelor’s degree from Stanford’s School of Engineering, Department of Architecture and an M.B.A. from Harvard Business School.

Push-out Score suggests push-out forces

It is not completely certain what forces eventually triggered Bill Dawson’s sudden move.

The Push-out Score™ determined by exechange suggests that push-out forces may have contributed to the management change.

Read the full story in the exechange report 27.2017 ($).